The formulary.
Every compound on the YOD formulary, with its category, pharmacy partner, and starting member rate. Eligibility is determined by intake and bloodwork — never by request. Most members are prescribed two to four compounds at any one time.
A further twelve compounds are in our four-wave roadmap, awaiting regulatory clearance: AOD-9604, DSIP, Epitalon, KPV, Selank, Semax, SS-31, Cerebrolysin, and four others. We add compounds to the formulary as the pathway clears, not before. The roadmap is in the member portal.
Two licensed compounders.
No grey market.
Strive Pharmacy
Primary partner. Covers Wave 1A — GLP-1s, Sermorelin, GHK-Cu, PT-141, NAD+, full HRT, methylene blue, sirolimus.
- 0112 peptides + 13 HRT lines
- 02Cold-chain shipped insulated
- 032–5 business-day fulfilment
Empower Pharmacy
Secondary partner. Covers Wave 1B — BPC-157, TB-500, Thymosin Alpha-1, MOTS-c, Ipamorelin / CJC. Live April 2026.
- 015 peptides live · Tesamorelin specialty
- 02503A + 503B dual licensure
- 03FDA Warning Letter (04/2025) closed out
Eligibility starts with bloodwork.
Nothing on this list is prescribed by request. Your panel and your clinician decide which compounds appear on your protocol — and which don't.